Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Virtual Tribunal Monastery
Indiana University
Thomas Jefferson University
The Christie NHS Foundation Trust
Wake Forest University Health Sciences
University of Leipzig
Jiangsu HengRui Medicine Co., Ltd.
University of Nebraska
Hamad Medical Corporation
University of Utah
Children's Mercy Hospital Kansas City
Emory University
University of Louisville
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Mesoblast, Ltd.
Rabin Medical Center
University of California, San Francisco